Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-gamma Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A(2)

Απλή σελίδα τεκμηρίου
dc.contributor.authorRizos, C. V.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorTellis, C. C.en
dc.contributor.authorFlorentin, M.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:54:03Z
dc.date.available2015-11-24T16:54:03Z
dc.identifier.issn1540-4196-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10107
dc.rightsDefault Licence-
dc.subjectcoronary-heart-diseaseen
dc.subjectldl particle-sizeen
dc.subjectacetylhydrolase activityen
dc.subjectinsulin sensitivityen
dc.subjecthypolipidemic drugsen
dc.subjecthypertensionen
dc.subjecttelmisartanen
dc.subjectrisken
dc.subjectatherosclerosisen
dc.subjectidentificationen
dc.titleCombining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-gamma Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A(2)en
heal.abstractBackground: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)). Some sartans partially activate peroxisome proliferator-activated receptor-g (PPAR gamma), possibly having a favorable effect on metabolic parameters. Telmisartan is the most potent partial PPAR gamma activator, followed by irbesartan, whereas olmesartan does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPAR gamma-activating capacity with rosuvastatin on LDL subfractions and plasma Lp-PLA(2) in patients with mixed dyslipidemia, hypertension, and prediabetes. Methods: Following dietary intervention, patients were allocated randomly to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n - 52) or irbesartan 300 mg/day (RI group, n - 48) or olmesartan 20 mg/day (RO group, n - 51). After 6 months of treatment, changes in LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass were evaluated blindly. Results: A total of 151 patients (73 male; mean age 60 years) were included. Large LDL-C decreased in the RT (-36%), RI (-39%), and RO (-41%) groups (P<0.001 for all vs. baseline). Small dense LDL-C decreased in the RT (-67%), RI (-58%), and RO (-61%) groups (P<0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline (RT+1.4%, P = 0.002; RI+1.0%, P = 0.04; and RO+1.4%, P = 0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA(2) activity decreased equally in all groups (RT -38%, RI -38%, RO -43%) (P<0.001 for all vs. baseline). Plasma Lp-PLA(2) mass decreased similarly in all groups versus baseline (RT -28%, P = 0.001; RI -32%, P = 0.01; and RO -27%, P = 0.001). No difference for the change of Lp-PLA(2) mass or activity was noticed among groups. Conclusions: The combination of rosuvastatin with sartans of different PPAR gamma-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDOI 10.1089/met.2010.0120-
heal.identifier.secondary<Go to ISI>://000291001200009-
heal.identifier.secondaryhttp://online.liebertpub.com/doi/pdfplus/10.1089/met.2010.0120-
heal.journalNameMetabolic Syndrome and Related Disordersen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ